Glutamatergic Modulation in Depression Management

Glutamate is the chief excitatory neurotransmitter in the mammalian brain and has emerged as a central focus in the pathophysiology and treatment of major depressive disorder. Traditional monoaminergic theories of depression have been complemented by an understanding of dysregulated glutamatergic signalling, particularly at N-methyl-D-aspartate receptors (NMDARs) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Antagonism of NMDARs by sub-anaesthetic doses of ketamine triggers a cascade of intracellular events, including activation of the mammalian target of rapamycin (mTOR) pathway and increased synaptic protein synthesis, culminating in rapid restoration of synaptic connectivity in key prefrontal and hippocampal circuits. Modulators of co-agonist binding sites, such as sarcosine and D-serine, likewise enhance receptor function and promote neuroplasticity. Emerging compounds targeting specific NMDAR subunits, G-protein-coupled metabotropic glutamate receptors and sigma-1 chaperone proteins offer further avenues for both rapid and sustained antidepressant efficacy. Clinical and preclinical studies reveal that glutamatergic interventions may alleviate treatment-resistant and chronic forms of depression, highlighting glutamate’s global significance as a target for next-generation therapeutics and the potential to transform contemporary management of mood disorders.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Glutamatergic Modulation in Depression Management publication trend

The graph below shows the total number of articles in glutamatergic modulation in depression management across all publications each year (not limited to Nature Index journals).

Technical terms

NMDA receptor (NMDAR): Ionotropic glutamate receptor that mediates calcium influx and is critical for long-term synaptic plasticity.

AMPAR: Ionotropic glutamate receptor mediating fast excitatory transmission and contributing to synaptic strengthening.

GluN2B: Regulatory subunit of NMDARs that influences receptor localisation and downstream signalling.

mTOR pathway: Intracellular kinase cascade controlling protein synthesis essential for synaptic formation and maintenance.

CaMKIIα: Calcium/calmodulin-activated kinase that regulates receptor phosphorylation and supports synaptic plasticity.

Extrasynaptic receptor: Receptor located outside the synaptic cleft, often mediating distinct signalling outcomes from synaptic receptors.

Metabotropic glutamate receptors (mGluRs): G-protein-coupled receptors that modulate neuronal excitability and neurotransmitter release.

Synaptic plasticity: The ability of synapses to strengthen or weaken over time in response to changes in activity.

References

1. Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov. Translational Psychiatry (2024).
2. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife (2014).
3. Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies. Frontiers in Psychiatry (2019).
4. Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan. PLOS ONE (2014).
5. Glutamate: The Master Neurotransmitter and Its Implications in Chronic Stress and Mood Disorders. Frontiers in Human Neuroscience (2021).
6. Extrasynaptic CaMKIIα is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model. Journal of Neuroinflammation (2020).
7. AMPA Receptor–mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role. Frontiers in Behavioral Neuroscience (2015).